RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Murali Yallapu to Cell Proliferation

This is a "connection" page, showing publications Murali Yallapu has written about Cell Proliferation.
Connection Strength

1.676
  1. Nagesh PKB, Chowdhury P, Hatami E, Jain S, Dan N, Kashyap VK, Chauhan SC, Jaggi M, Yallapu MM. Tannic acid inhibits lipid metabolism and induce ROS in prostate cancer cells. Sci Rep. 2020 01 22; 10(1):980.
    View in: PubMed
    Score: 0.404
  2. Tiwari R, Delossantos J, Ghali ENHK, Chavez LA, Chaudhari VS, Han S, Chauhan SC, Yallapu MM. Biodegradable PCL-PLGA Electrospun Nanofibers for Localized Cancer Therapy. ACS Appl Bio Mater. 2026 May 18; 9(10):4579-4593.
    View in: PubMed
    Score: 0.156
  3. Chauhan N, Dhasmana A, Jaggi M, Chauhan SC, Yallapu MM. miR-205: A Potential Biomedicine for Cancer Therapy. Cells. 2020 08 25; 9(9).
    View in: PubMed
    Score: 0.105
  4. Kashyap VK, Wang Q, Setua S, Nagesh PKB, Chauhan N, Kumari S, Chowdhury P, Miller DD, Yallapu MM, Li W, Jaggi M, Hafeez BB, Chauhan SC. Therapeutic efficacy of a novel ?III/?IV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res. 2019 Jan 23; 38(1):29.
    View in: PubMed
    Score: 0.094
  5. Chowdhury P, Nagesh PKB, Hatami E, Wagh S, Dan N, Tripathi MK, Khan S, Hafeez BB, Meibohm B, Chauhan SC, Jaggi M, Yallapu MM. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. J Colloid Interface Sci. 2019 Feb 01; 535:133-148.
    View in: PubMed
    Score: 0.092
  6. Hafeez BB, Ganju A, Sikander M, Kashyap VK, Hafeez ZB, Chauhan N, Malik S, Massey AE, Tripathi MK, Halaweish FT, Zafar N, Singh MM, Yallapu MM, Chauhan SC, Jaggi M. Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic ?-catenin Signaling and EMT Progression. Mol Cancer Ther. 2017 10; 16(10):2267-2280.
    View in: PubMed
    Score: 0.084
  7. Nagesh PKB, Johnson NR, Boya VKN, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW, Zafar N, Chauhan SC, Jaggi M, Yallapu MM. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces. 2016 Aug 01; 144:8-20.
    View in: PubMed
    Score: 0.078
  8. Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, Khan S, Jaggi M, Chauhan SC. Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. Biomaterials. 2015 Apr; 46:1-12.
    View in: PubMed
    Score: 0.071
  9. Yallapu MM, Khan S, Maher DM, Ebeling MC, Sundram V, Chauhan N, Ganju A, Balakrishna S, Gupta BK, Zafar N, Jaggi M, Chauhan SC. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials. 2014 Oct; 35(30):8635-48.
    View in: PubMed
    Score: 0.069
  10. Yallapu MM, Ebeling MC, Khan S, Sundram V, Chauhan N, Gupta BK, Puumala SE, Jaggi M, Chauhan SC. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Mol Cancer Ther. 2013 Aug; 12(8):1471-80.
    View in: PubMed
    Score: 0.064
  11. Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab. 2012 Jan; 13(1):120-8.
    View in: PubMed
    Score: 0.058
  12. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 2010 Nov 01; 351(1):19-29.
    View in: PubMed
    Score: 0.052
  13. Yallapu MM, Jaggi M, Chauhan SC. beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B Biointerfaces. 2010 Aug 01; 79(1):113-25.
    View in: PubMed
    Score: 0.051
  14. Gao Y, Chen W, Zarogoulidis P, Yallapu MM, Nikolic MV, Vaishnani DK, Zheng J, Nedeljkovic N, Ye K, Guo Y, Xu Q. Multiomics and experimental validation reveal theophylline's mechanism targeting IL1A/ACTB/TLR4 and identify synergistic drugs in hepatocellular carcinoma. J Pharmacol Exp Ther. 2026 Mar; 393(3):103836.
    View in: PubMed
    Score: 0.038
  15. Ahmad M, Alvi SS, Ahsan H, Perez C, Massey A, Kashyap VK, Chauhan N, Anning E, Tripathi MK, Kim DJ, Sahoo N, Oraby T, Yallapu MM, Khan MM, Sebastian MM, Chauhan SC, Hafeez BB. Ubiquitination of Oncogenic Mutant p53 via Attenuation of Ribosome Biogenesis Machinery Effectively Inhibits Pancreatic Tumor Growth. Mol Cancer Ther. 2026 Feb 04; 25(2):257-271.
    View in: PubMed
    Score: 0.038
  16. Sikander M, Malik S, Khan S, Kumari S, Chauhan N, Khan P, Halaweish FT, Chauhan B, Yallapu MM, Jaggi M, Chauhan SC. Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer). Cells. 2019 Dec 31; 9(1).
    View in: PubMed
    Score: 0.025
  17. Kumari S, Khan S, Sekhri R, Mandil H, Behrman S, Yallapu MM, Chauhan SC, Jaggi M. Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. Br J Cancer. 2020 01; 122(1):121-131.
    View in: PubMed
    Score: 0.025
  18. Chauhan N, Maher DM, Hafeez BB, Mandil H, Singh MM, Yallapu MM, Jaggi M, Chauhan SC. Ormeloxifene nanotherapy for cervical cancer treatment. Int J Nanomedicine. 2019; 14:7107-7121.
    View in: PubMed
    Score: 0.025
  19. Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine. 2019 08; 20:102027.
    View in: PubMed
    Score: 0.024
  20. Khan S, Setua S, Kumari S, Dan N, Massey A, Hafeez BB, Yallapu MM, Stiles ZE, Alabkaa A, Yue J, Ganju A, Behrman S, Jaggi M, Chauhan SC. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Biomaterials. 2019 07; 208:83-97.
    View in: PubMed
    Score: 0.024
  21. Kumar BNP, Puvvada N, Rajput S, Sarkar S, Mahto MK, Yallapu MM, Pathak A, Emdad L, Das SK, Reis RL, Kundu SC, Fisher PB, Mandal M. Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer. Mol Pharm. 2018 07 02; 15(7):2698-2713.
    View in: PubMed
    Score: 0.023
  22. Setua S, Khan S, Yallapu MM, Behrman SW, Sikander M, Khan SS, Jaggi M, Chauhan SC. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. J Gastrointest Surg. 2017 01; 21(1):94-105.
    View in: PubMed
    Score: 0.020
  23. Zaman MS, Chauhan N, Yallapu MM, Gara RK, Maher DM, Kumari S, Sikander M, Khan S, Zafar N, Jaggi M, Chauhan SC. Curcumin Nanoformulation for Cervical Cancer Treatment. Sci Rep. 2016 Feb 03; 6:20051.
    View in: PubMed
    Score: 0.019
  24. Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N, Singh MM, Jaggi M, Chauhan SC. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Res. 2015 Jun 01; 75(11):2292-304.
    View in: PubMed
    Score: 0.018
  25. Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials. 2015; 53:731-43.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support